CompletedInterventionalPhase 1Last updated Jun 5, 2025

Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)

A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Dose Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-6194 in Participants With Moderate to Severe Atopic Dermatitis

Overview

ClinicalTrials.gov ID: NCT05450198
Lead Sponsor: Merck Sharp & Dohme LLCINDUSTRY
Brief Summary: The primary objective of this study is to characterize the safety and tolerability of MK-6194 following multiple doses among participants with moderate to severe atopic dermatitis who are unresponsive to other therapies.
Study Type: Interventional

Status

Overall Status: Completed
Start Date: Aug 8, 2022Actual
Primary Completion Date: May 22, 2024Actual
Completion Date: May 22, 2024Actual

Study Record Dates

First Submitted: Jul 5, 2022
First Submitted that Met QC Criteria: Jul 5, 2022
First Posted: Jul 8, 2022Actual
Last Update Submitted that Met QC Criteria: Jun 3, 2025
Last Update Posted: Jun 5, 2025Actual
Last Verified: May 2025

NCT01732510Terminated

A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003)

NCT06821334Completed

A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014)

NCT04836858Completed

A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis.

NCT02549014Completed

A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)

NCT05859724Terminated

Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)

NCT04643457Completed

A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis